RxDoctor Payments Data

Yazan Alderazi, MD

Vascular Neurology · Webster, TXNPI 1316113251

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,850 of the $9,711 with a category attached, or 60.2%. Medical Device Business Services, Inc. accounts for 66.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $5,026 and has fallen 91.6% since, to $421 in 2025.

$9,711in general payments, 2019–2025

Across 73 payments — averaging $133.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$6K
  • Johnson & Johnson$839
  • Microvention, Inc.$554
  • Route 92 Medical, Inc.$427
  • Siemens Medical Solutions USA, Inc.$339
  • Imperative Care, Inc$272
  • plus $786 from 9 others
$17,491in research payments, 2019–2025

Across 16 payments — averaging $1093.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Penumbra, Inc.$17K

What the payments were for

  • Consulting fees$5,85060%
  • Travel & lodging$8158%
  • Food & beverage$3,04731%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,711 in reported general payments places this provider in the 80th percentile of 76 vascular neurology providers in Texas.

See all vascular neurology providers in Texas

Medicare billing

Part B allowed, 2024
$32,015
Medicare patients
33
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor11$4,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$78$4,78311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 76 vascular neurology providers in Texas.

Other vascular neurology in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →